- Home
- NDLS vs FGEN Comparison
NDLS vs FGEN Comparison
Compare NDLS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- FGEN
- Stock Information
- Founded
- NDLS 1995
- FGEN 1993
- Country
- NDLS United States
- FGEN United States
- Employees
- NDLS N/A
- FGEN N/A
- Industry
- NDLS Restaurants
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- FGEN Health Care
- Exchange
- NDLS Nasdaq
- FGEN Nasdaq
- Market Cap
- NDLS 32.9M
- FGEN 33.5M
- IPO Year
- NDLS 2013
- FGEN 2014
- Fundamental
- Price
- NDLS $0.82
- FGEN $5.79
- Analyst Decision
- NDLS Strong Buy
- FGEN Strong Buy
- Analyst Count
- NDLS 2
- FGEN 1
- Target Price
- NDLS $3.00
- FGEN $250.00
- AVG Volume (30 Days)
- NDLS 212.2K
- FGEN 60.4K
- Earning Date
- NDLS 08-06-2025
- FGEN 08-05-2025
- Dividend Yield
- NDLS N/A
- FGEN N/A
- EPS Growth
- NDLS N/A
- FGEN N/A
- EPS
- NDLS N/A
- FGEN N/A
- Revenue
- NDLS $495,670,000.00
- FGEN $6,996,000.00
- Revenue This Year
- NDLS $5.37
- FGEN N/A
- Revenue Next Year
- NDLS $0.68
- FGEN N/A
- P/E Ratio
- NDLS N/A
- FGEN N/A
- Revenue Growth
- NDLS N/A
- FGEN N/A
- 52 Week Low
- NDLS $0.55
- FGEN $4.50
- 52 Week High
- NDLS $1.83
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- NDLS 51.14
- FGEN 43.29
- Support Level
- NDLS $0.66
- FGEN $5.37
- Resistance Level
- NDLS $0.85
- FGEN $5.73
- Average True Range (ATR)
- NDLS 0.07
- FGEN 0.41
- MACD
- NDLS 0.01
- FGEN 0.07
- Stochastic Oscillator
- NDLS 80.00
- FGEN 77.78
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.